首页> 外文期刊>American Journal of Cancer Research >Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study
【24h】

Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study

机译:台湾埃内切韦或替诺维尔治疗肝硬化肝硬化患者肝细胞癌发生率的比较 - 回顾性研究

获取原文
获取外文期刊封面目录资料

摘要

Whether tenofovir disoproxil fumarate (TDF) is superior to entecavir in lowering the risk of hepatocellular carcinoma (HCC) development remains controversial. This retrospective study compared the incidences of HCC, cirrhotic events, and mortality between patients treated with entecavir and TDF. The study enrolled 1560 chronic hepatitis B (CHB) patients with cirrhosis from 2008 through 2018. All patients received entecavir or TDF monotherapy for at least 12 months before enrollment. Patients who had HCC or liver transplantation at initial treatment or within the first year of entecavir or TDF therapy were excluded. In the entire cohort, the cumulative incidence rates of HCC at 3, 5, and 10 years were 9.5%, 15.2%, and 25.4%, respectively. The entecavir group had a higher cumulative incidence of HCC than the TDF group ( P = 0.001). A Cox regression analysis showed that entecavir group, old age, male sex, hepatic decompensation, diabetes mellitus, lower albumin levels, and platelet count were independent predictors of HCC. TDF treatment was significantly associated with a lower risk of HCC compared to entecavir treatment after adjustment with propensity score matching or inverse probability of treatment weighting in all patients. However, this association was not observed in patients with compensated cirrhosis at entry or patients enrolled after 2011, including after adjustment with propensity score matching or inverse probability of treatment weighting. No significant differences were observed in cirrhotic events and mortality or liver transplantation between the entecavir and TDF groups. In conclusion, the incidences of HCC did not differ significantly between patients with compensated cirrhosis or those enrolled over the same period treated with entecavir or TDF.
机译:Tenofovir Disoproxil umarate(TDF)优于埃内斯切韦,降低肝细胞癌(HCC)发展的风险仍存在争议。这种回顾性研究比较了HCC,肝硬化事件和用恩替卡韦治疗的患者之间的死亡率的发生率。该研究从2008年至2018年开始注册了1560名慢性乙型肝炎(CHB)肝硬化患者。所有患者在入学前至少12个月内接受Entecavir或TDF单药治疗。患有HCC或肝移植在初始治疗中或在埃内斯卡韦或TDF治疗的第一年内进行的患者被排除在外。在整个队列中,3,5和10岁的HCC累积发病率分别为9.5%,15.2%和25.4%。恩替卡韦组的HCC累积发病率高于TDF组(P = 0.001)。 COX回归分析表明,恩昔韦群体,晚年,男性,肝脏失代偿,糖尿病,较低的白蛋白水平和血小板计数是HCC的独立预测因子。与在所有患者的倾向评分匹配或治疗加权的倾向匹配或逆概率调整后,TDF治疗与HCC的风险较低。然而,在2011年以后注册的进入或患者的补偿肝硬化患者未观察到这种关联,包括在调整后与倾向评分匹配或治疗加权的反常概率进行调整。在entecavir和TDF组之间,在肝硬化事件和死亡率或肝移植中没有观察到显着差异。总之,HCC的发病率与补偿肝硬化的患者之间没有显着差异,或者在患有Entecavir或TDF治疗相同的时间内注册的患者之间没有差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号